Sign in

    Ahu Demir • Ladenburg Thalmann

    Ahu Demir's questions to Immunocore Holdings PLC (IMCR) leadership

    Ahu Demir's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Ahu Demir of Ladenburg Thalmann asked about the expected patient numbers and mono/combo split for the upcoming lung cancer data, and what would provide confidence to advance the HIV program after the MAD data.

    Answer

    Mohammed Dar, an executive, said the lung cancer dataset will likely be smaller than melanoma/ovarian, with more combo than mono patients. David Berman, Head of R&D, explained that for the HIV program, any evidence of antiviral activity, such as reducing the viral reservoir or delaying rebound, would be intriguing and sufficient to continue, as this has never been achieved before.

    Ask Fintool Equity Research AI

    Ahu Demir's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Ahu Demir of Ladenburg Thalmann inquired about the expected patient numbers and mono-versus-combo split for the upcoming lung cancer data, and asked what results from the HIV MAD data would provide confidence to advance the program.

    Answer

    Mohammed Dar, an executive, indicated the lung cancer dataset will be smaller than previous readouts, with more combo than mono patients. David Berman, Head of R&D, explained that for the pioneering HIV program, any evidence of antiviral activity, such as reducing the viral reservoir or delaying rebound, would be intriguing and support continuation.

    Ask Fintool Equity Research AI